KR20180015158A - L-４-클로로키누레닌의 치료적 용도 - Google Patents

L-４-클로로키누레닌의 치료적 용도 Download PDF

Info

Publication number
KR20180015158A
KR20180015158A KR1020177036471A KR20177036471A KR20180015158A KR 20180015158 A KR20180015158 A KR 20180015158A KR 1020177036471 A KR1020177036471 A KR 1020177036471A KR 20177036471 A KR20177036471 A KR 20177036471A KR 20180015158 A KR20180015158 A KR 20180015158A
Authority
KR
South Korea
Prior art keywords
chloroquinolenine
depression
dose
treatment
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177036471A
Other languages
English (en)
Korean (ko)
Inventor
에이치. 랠프 스노드그래스
Original Assignee
비스타젠 쎄라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비스타젠 쎄라퓨틱스, 인크. filed Critical 비스타젠 쎄라퓨틱스, 인크.
Priority to KR1020247014693A priority Critical patent/KR20240068766A/ko
Publication of KR20180015158A publication Critical patent/KR20180015158A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177036471A 2015-05-22 2016-05-23 L-４-클로로키누레닌의 치료적 용도 Ceased KR20180015158A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247014693A KR20240068766A (ko) 2015-05-22 2016-05-23 L-４-클로로키누레닌의 치료적 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562179924P 2015-05-22 2015-05-22
US62/179,924 2015-05-22
PCT/US2016/033733 WO2016191351A1 (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247014693A Division KR20240068766A (ko) 2015-05-22 2016-05-23 L-４-클로로키누레닌의 치료적 용도

Publications (1)

Publication Number Publication Date
KR20180015158A true KR20180015158A (ko) 2018-02-12

Family

ID=57393671

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177036471A Ceased KR20180015158A (ko) 2015-05-22 2016-05-23 L-４-클로로키누레닌의 치료적 용도
KR1020247014693A Ceased KR20240068766A (ko) 2015-05-22 2016-05-23 L-４-클로로키누레닌의 치료적 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247014693A Ceased KR20240068766A (ko) 2015-05-22 2016-05-23 L-４-클로로키누레닌의 치료적 용도

Country Status (19)

Country Link
US (3) US20180140568A1 (https=)
EP (2) EP4108239A1 (https=)
JP (3) JP2018521007A (https=)
KR (2) KR20180015158A (https=)
CN (1) CN107949379A (https=)
AU (3) AU2016268153B2 (https=)
BR (1) BR112017024908A2 (https=)
CA (1) CA3024783A1 (https=)
DK (1) DK3297619T3 (https=)
EA (1) EA201792571A1 (https=)
ES (1) ES2925274T3 (https=)
IL (3) IL296380A (https=)
MX (1) MX395492B (https=)
PL (1) PL3297619T3 (https=)
PT (1) PT3297619T (https=)
SG (1) SG10202007661XA (https=)
SI (1) SI3297619T1 (https=)
WO (1) WO2016191351A1 (https=)
ZA (1) ZA201707874B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3598971T (pt) 2013-01-22 2024-06-20 Vistagen Therapeutics Inc ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CA3136418A1 (en) * 2019-04-09 2020-10-15 Vistagen Therapeutics, Inc. Genetic variants associated with response to treatment of neurological disorders
JP7805969B2 (ja) * 2020-06-24 2026-01-26 バイオヘイブン・セラピューティクス・リミテッド 強迫性障害を治療するための組成物及び方法
WO2022221423A1 (en) * 2021-04-13 2022-10-20 Vistagen Therapeutics, Inc. Treatment of autoimmune anti-nmda-receptor encephalitis
CN115677519A (zh) * 2021-07-22 2023-02-03 立科时代(武汉)生物科技有限公司 L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用
WO2024011105A1 (en) * 2022-07-05 2024-01-11 Mahana Therapeutics, Inc. Methods and systems for treating tinnitus using digital therapeutics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
EP1061924A1 (en) * 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
CN1486180A (zh) * 2000-12-07 2004-03-31 纽热莫勒丘乐有限公司 用nmda受体拮抗物治疗神经精神病紊乱的方法
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
AU2007235876A1 (en) * 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
US8058243B2 (en) * 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
WO2009061935A2 (en) * 2007-11-06 2009-05-14 Emory University Methods of identifying safe nmda receptor antagonists
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
KR20150096370A (ko) * 2012-08-23 2015-08-24 스튜어트 엘. 웨그 항불안제 조성물, 제형 및 사용방법
PT3598971T (pt) * 2013-01-22 2024-06-20 Vistagen Therapeutics Inc ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina
WO2014152835A1 (en) 2013-03-14 2014-09-25 Vistagen Therapeutics, Inc. Synthesis of chiral kynurenine compounds and intermediates
CN107417558A (zh) 2013-03-14 2017-12-01 维斯塔津治疗公司 用于合成手性犬尿氨酸化合物的方法
KR20170013890A (ko) * 2014-05-06 2017-02-07 노쓰웨스턴유니버시티 Nmdar 조절 화합물의 조합물

Also Published As

Publication number Publication date
KR20240068766A (ko) 2024-05-17
EP3297619B1 (en) 2022-07-06
AU2023282234A1 (en) 2024-01-18
EA201792571A1 (ru) 2018-06-29
SG10202007661XA (en) 2020-09-29
US20180140568A1 (en) 2018-05-24
AU2021209279B2 (en) 2023-09-14
MX2017014456A (es) 2018-03-16
MX395492B (es) 2025-03-25
IL255770B (en) 2021-09-30
JP2024050575A (ja) 2024-04-10
ES2925274T3 (es) 2022-10-14
US20240122887A1 (en) 2024-04-18
JP2022064908A (ja) 2022-04-26
AU2021209279A1 (en) 2021-08-19
CA3024783A1 (en) 2016-12-01
WO2016191351A1 (en) 2016-12-01
US20190321317A1 (en) 2019-10-24
EP3297619A4 (en) 2019-01-02
HK1257800A1 (en) 2019-11-01
EP3297619A1 (en) 2018-03-28
AU2016268153A1 (en) 2017-12-14
IL296380A (en) 2022-11-01
PL3297619T3 (pl) 2023-02-13
DK3297619T3 (da) 2022-08-15
JP2018521007A (ja) 2018-08-02
SI3297619T1 (sl) 2023-02-28
IL285882A (en) 2021-09-30
PT3297619T (pt) 2022-08-05
ZA201707874B (en) 2020-01-29
IL255770A (en) 2018-01-31
EP4108239A1 (en) 2022-12-28
BR112017024908A2 (pt) 2018-07-31
CN107949379A (zh) 2018-04-20
AU2016268153B2 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
AU2021209279B2 (en) Therapeutic uses of L-4-chlorokynurenine
Zuddas et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation
Post et al. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response
Sullivan et al. Essential tremor: epidemiology, diagnosis, and treatment
CN101208092A (zh) 用于处理精神障碍的方法和组合物
AU2011313814B2 (en) Combination therapy for the treatment of depression and other non-infectious diseases
JP2019023195A (ja) Ｌ−４−クロロキヌレニンの剤形及び治療的使用
Karp et al. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability.
WO2018075481A1 (en) Compounds, compositions and methods for treating or preventing depression and other diseases
US7915262B2 (en) Combination preparations comprising SLV308 and a dopamine agonist
JP2008509147A (ja) ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用
HK1257800B (en) Therapeutic uses of l-4-chlorokynurenine
Abdel-Hamid Pharmacologic treatment of rapid ejaculation: levels of evidence-based review
CA2654719A1 (en) Combination preparations comprising slv308 and a l-dopa
TWI752282B (zh) 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途
JP2008513430A (ja) 月経前症候群および月経前不快気分障害の処置のためのピンドロール
WO2024211216A1 (en) Cilnidipine and a p-glycoprotein inhibitor for treating pain
Combos How Long Until It Works
HK1116664A (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease
WO2010136964A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210521

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230302

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231201

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230302

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20240603

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230302

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20240603

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20240430

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20210521